Nyström C, Hällström T
Acta Psychiatr Scand. 1985 Jul;72(1):6-15. doi: 10.1111/j.1600-0447.1985.tb02563.x.
Seventy-five outpatients with major depressive disorder (RDC) were randomly referred to treatment with a dominant serotonin (5-HT) uptake inhibiting drug (zimeldine, 100 mg b.i.d.) or a dominant noradrenaline (NA) uptake inhibiting drug, (maprotiline, 75 mg b.i.d.). The total antidepressive effect was similar in the two groups for up to 4 weeks of treatment. Both drugs gave an effect on the depressive syndrome as a whole, with no preference for mood, anxiety, retardation or vital symptoms. Good response to the NA drug correlated to few prior episodes and few years since first episode, whereas the 5-HT drug had its best effect when there were several previous episodes.
75例符合研究诊断标准（RDC）的门诊重度抑郁症患者被随机分配接受主要抑制血清素（5-HT）摄取的药物（齐美利定，每日2次，每次100毫克）或主要抑制去甲肾上腺素（NA）摄取的药物（马普替林，每日2次，每次75毫克）治疗。在长达4周的治疗中，两组的总体抗抑郁效果相似。两种药物对整个抑郁综合征均有疗效，对情绪、焦虑、迟缓或生命体征无明显偏好。对NA药物反应良好与既往发作次数少及首次发作后年限短相关，而5-HT药物在既往发作次数较多时效果最佳。
